<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086160</url>
  </required_header>
  <id_info>
    <org_study_id>HSEARS20190518001</org_study_id>
    <nct_id>NCT04086160</nct_id>
  </id_info>
  <brief_title>Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset</brief_title>
  <official_title>Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr WANG Shumei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hong Kong Polytechnic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this research are to investigate (1) if schizophrenia patients and at-risk
      individuals present bradykinesia and dyskinesia and (2) if tDCS improves motor performance in
      schizophrenia patients and at-risk individuals. The first hypothesis is that both
      schizophrenia patients and at-risk individuals show bradykinesia and dyskinesia, and the
      motor symptoms are more severe in the former than the latter. The second hypothesis is that
      tDCS improves motor performance in schizophrenia patients and at-risk cases.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right before the 1st session of tDCS</time_frame>
    <description>normalized movement time (representing severity of parkinsonism). Unit: second/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right after the 8th (last) session of tDCS</time_frame>
    <description>normalized movement time (representing severity of parkinsonism). Unit: second/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right before the 1st session of tDCS</time_frame>
    <description>normalized number of movement units (representing severity of dyskinesia). Unit: units/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right after the 8th (last) session of tDCS</time_frame>
    <description>normalized number of movement units (representing severity of dyskinesia). Unit: units/mm</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychosis</condition>
  <condition>Parkinsonism</condition>
  <condition>Dyskinesias</condition>
  <arm_group>
    <arm_group_label>schizophrenia- tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>schizophrenia- sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>at risk- tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>at risk- sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls for schizophrenia- tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls for schizophrenia- sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls for at risk- tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls for at risk- sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation device (Soterix Medical, New York, NY)</intervention_name>
    <description>Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.</description>
    <arm_group_label>at risk- sham</arm_group_label>
    <arm_group_label>at risk- tDCS</arm_group_label>
    <arm_group_label>healthy controls for at risk- sham</arm_group_label>
    <arm_group_label>healthy controls for at risk- tDCS</arm_group_label>
    <arm_group_label>healthy controls for schizophrenia- sham</arm_group_label>
    <arm_group_label>healthy controls for schizophrenia- tDCS</arm_group_label>
    <arm_group_label>schizophrenia- sham</arm_group_label>
    <arm_group_label>schizophrenia- tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for schizophrenia patients:

          -  a diagnosis of schizophrenia without other psychiatric diseases

          -  having stable psychotic symptoms

          -  a score of 22 or above in Hong Kong version Montreal Cognitive Assessment

          -  having no neurological diseases and no medical conditions that affect motor
             performance

        No Exclusion Criteria.

        Inclusion Criteria for at-risk individuals:

          -  a score of nine or above in the Chinese version of the 16-item Prodromal Questionnaire
             (CPQ-16)

          -  a score of 22 or above in Hong Kong version Montreal Cognitive Assessment

          -  having no diagnosis of psychiatric diseases

          -  having no neurological diseases and no medical conditions that affect motor
             performance

        No Exclusion Criteria.

        Inclusion Criteria for healthy controls:

          -  a score less than nine in CPQ-16

          -  a score of 22 or above in Hong Kong version Montreal Cognitive Assessment

          -  having no diagnosis of psychiatric diseases

          -  having no neurological diseases and no medical conditions that affect motor
             performance.

        No Exclusion Criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hong Kong Polytechnic University</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Hong Kong Polytechnic University</investigator_affiliation>
    <investigator_full_name>Dr WANG Shumei</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

